Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

GAVRETO (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., Sept. 17, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for GAVRETOTM (pralsetinib) for the treatment of adult patients with metastatic RET fusion-p... (Source: McKesson News)
Source: McKesson News - September 17, 2020 Category: Information Technology Source Type: news

PET shows promise for detecting NSCLC recurrence
F-18 FDG PET/CT shows promise for detecting recurrence of disease in non-small...Read more on AuntMinnie.comRelated Reading: PET radiomics tailor head/neck cancer treatment Nuclear medicine volume plummets due to COVID-19 Dual-phase technique improves PET/CT brain tumor imaging PET/CT could be useful for diagnosing fever PET/MRI ups lesion detection by 15% for some cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

NICE recommends lung cancer treatment
Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published by NICE recommending osimertinib (also called Tagrisso and made by AstraZeneca) at two different places in the treatment pathway for locally advanced or metastatic epidermal growth factor receptor (EGFR)-positive NSCLC. (Source: NHS Networks)
Source: NHS Networks - September 15, 2020 Category: UK Health Source Type: news

PET radiomics tailor head/neck cancer treatment
Radiomic factors -- that is, image-based tumor phenotypes -- gleaned from F-18...Read more on AuntMinnie.comRelated Reading: Dual-phase technique improves PET/CT brain tumor imaging PET/CT could be useful for diagnosing fever PET/MRI ups lesion detection by 15% for some cancers Radiomics can predict treatment outcome for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 10, 2020 Category: Radiology Source Type: news

FDA approves pralsetinib for lung cancer with RET gene fusions
On September 4, 2020, the Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Pralsetinib: Second Drug for RET+ NSCLC Approved in US Pralsetinib: Second Drug for RET+ NSCLC Approved in US
Another drug is now approved for use in patients with non-small cell lung cancer whose tumors harbor RET fusions, which are found in approximately 1% to 2% of cases.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
CDx approval expands clinical utility of Oncomine Dx Target Test to identify candidates for GAVRETO CARLSBAD, Calif., Sept. 8, 2020 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration (FDA) has granted premarket approval ... Diagnostics, Oncology, FDA Thermo Fisher Scientific, Oncomine Dx Target, NSCLC, GAVRETO, pralsetinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Media News - September 7, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Investor Update - September 7, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
South San Francisco, CA -- September 4, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 4, 2020 Category: Drugs & Pharmacology Source Type: news

First Drug for MET+ NSCLC Shows High Response Rates First Drug for MET+ NSCLC Shows High Response Rates
Capmatinib, the first drug that targets non-small cell lung cancer (NSCLC) harboring MET mutations, produced impressive responses, especially in treatment-naive patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Attacking tumors from the inside
(UT Southwestern Medical Center) A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer (NSCLC), helping to suppress the tumor's growth and spread, UT Southwestern researchers report. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 3, 2020 Category: International Medicine & Public Health Source Type: news

Treatments linked to drop in lung cancer deaths
Deaths from the most common lung cancer, non-small cell lung cancer, declined sharply after 2013, faster than the drop in new cases of the disease. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - August 28, 2020 Category: Consumer Health News Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - August 28, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Media News - August 28, 2020 Category: Pharmaceuticals Source Type: news

Selpercatinib'Poised to Alter the Landscape' of RET+ve Cancers Selpercatinib'Poised to Alter the Landscape' of RET+ve Cancers
Selpercatinib induced high response rates in patients with RET-altered non-small cell lung cancer and medullary thyroid cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
(University of Texas M. D. Anderson Cancer Center) For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 26, 2020 Category: International Medicine & Public Health Source Type: news

FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Tepotinib granted Priority Review and is being evaluated under FDA Real-Time Oncology Review (RTOR) pilot program Tepotinib is a highly targeted inhibitor of c-MET that is administered as a once-daily oral tablet Data show robust, consistent and dura... Biopharmaceuticals, Oncology, FDA EMD Serono, Merck KGaA, Tepotinib, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 25, 2020 Category: Pharmaceuticals Source Type: news

FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
ROCKLAND, Mass., Aug. 25, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 25, 2020 Category: Drugs & Pharmacology Source Type: news

New Lung Cancer Trial Could Benefit Mesothelioma Patients
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II clinical research trial is focusing on non-small cell lung cancer and will enroll approximately 66 patients across the U.S. Keytruda, Merck’s anti-PD-1 therapy, works as a checkpoint inhibitor and allows the immune system to identify and attack cancer cells hiding within the PD-1 pathway. The FDA approved Keytruda for mesothelioma as the first immunotherapy treatment for the disease in 2020. Novocure, a global oncology company, has been developing...
Source: Asbestos and Mesothelioma News - August 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Why Are Oncologists Deviating From Best Evidence in NSCLC? Why Are Oncologists Deviating From Best Evidence in NSCLC?
Bringing practices in line with standard of care requires understanding why they're diverging in the first place, says Dr Jack West.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality m... Biopharmaceuticals, Oncology, Licensing Innovent Biologics, Eli Lilly, TYVYT, sintilimab, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 18, 2020 Category: Pharmaceuticals Source Type: news

Lung cancer deaths in U.S. fall by up to 6% annually, analysis finds
Deaths from non-small cell lung cancer in the United States declined by at least 3% a year on average between 2006 and 2016, according to an analysis published Wednesday by the New England Journal of Medicine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 12, 2020 Category: Consumer Health News Source Type: news

Targeted treatments help reduce death rates for most common lung cancer, study finds
Mortality rates for the most common type of lung cancer -- non-small cell lung caner -- have fallen significantly in recent years as a result of new treatments, according to a study by the National Cancer Institute. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - August 12, 2020 Category: Consumer Health News Authors: Laurie McGinley Source Type: news

NSCLC Success Story: Mortality Down, Survival Improved NSCLC Success Story: Mortality Down, Survival Improved
Mortality rates have fallen and survival has improved for patients with non-small cell lung cancer (NSCLC) in recent years, owing to new drug treatments, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Sharp Drop in Non-Small Cell Lung Cancer Mortality Seen in Recent Years
WEDNESDAY, Aug. 12, 2020 -- Mortality from non-small-cell lung cancer (NSCLC) in the United States fell sharply from 2013 to 2016, while survival improved substantially, according to a study published in the Aug. 13 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
SUZHOU, China, Aug. 12, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the ... Biopharmaceuticals, Oncology, Regulatory Innovent Biologics, Eli Lilly, TYVYT, sintilimab, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 12, 2020 Category: Pharmaceuticals Source Type: news

New treatments spur sharp reduction in lung cancer mortality rate
(NIH/National Cancer Institute) According to a new study, mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment. The study was led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. The findings were published August 12, 2020 in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 12, 2020 Category: Cancer & Oncology Source Type: news

Sintilimab Scintillates in First-line Non-squamous NSCLC Sintilimab Scintillates in First-line Non-squamous NSCLC
The investigational immunotherapy shows progression-free survival rates comparable to pembrolizumab when added to standard chemotherapy in non-squamous NSCLC, but mature survival data are awaited.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Checkpoint inhibitor use increases healthcare costs in NSCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

Gefitinib Plus Chemo for NSCLC With EGFR Mutations Gefitinib Plus Chemo for NSCLC With EGFR Mutations
Dr Mark Kris discusses recent studies that provide evidence for a new standard of care -- gefitinib plus chemotherapy -- in patients with NSCLC and an EGFR-activating mutation.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 27, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Radiomics can predict treatment outcome for NSCLC
Radiomics features on pretreatment FDG-PET exams can foretell outcomes in patients...Read more on AuntMinnie.comRelated Reading: AI improves interpretation of CT lung cancer images Diagnostic brain imaging overused for lung cancer AI predicts lung cancer survival from CT scan data AI, radiomics can help predict chemotherapy response New SPECT tracer targets NSCLC receptor (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 27, 2020 Category: Radiology Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other t...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Should ADAURA Trial Results Change Practice in NSCLC? Should ADAURA Trial Results Change Practice in NSCLC?
Dr Mark Kris says yes and explains why he thinks 3-year treatment with osimertinib should become the new standard of care for patients with EGFR mutation – positive NSCLC.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2020 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

AI improves interpretation of CT lung cancer images
An artificial intelligence (AI) neural network used with lung CT scans can...Read more on AuntMinnie.comRelated Reading: Diagnostic brain imaging overused for lung cancer Mobile CT improves access to lung cancer screening AI predicts lung cancer survival from CT scan data SABR plus surgery is effective for treating lung cancer New SPECT tracer targets NSCLC receptor (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 26, 2020 Category: Radiology Source Type: news

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath enterprise software, a universal digital platform for case management, collabo...
Source: Roche Media News - June 26, 2020 Category: Pharmaceuticals Source Type: news

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
             Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath ...
Source: Roche Investor Update - June 26, 2020 Category: Pharmaceuticals Source Type: news

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Chris Arendt, Ph.D., a leader of Takeda’s oncology team to discuss how the company is ensuring cancer research and medicines continue to benefit patients in the age of COVID-19.“The new normal” has been used to describe the challenging and dy...
Source: The Catalyst - June 24, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: PhRMA Member Company Cancer Coronavirus Source Type: news

Racial Disparities Seen in PET/CT Imaging for Lung Cancer
Black, Hispanic patients less likely to receive recommended imaging at time of diagnosis of NSCLC (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 23, 2020 Category: Respiratory Medicine Tags: Oncology, Pulmonology, Radiology, Journal, Source Type: news

Highlights in Non-Small Cell Lung Cancer From ASCO 2020 Highlights in Non-Small Cell Lung Cancer From ASCO 2020
Dr Mark Kris reports on key studies in NSCLC from ASCO 2020, including the practice-changing ADAURA trial, results on an antibody-drug conjugate targeting HER2, and data on a new checkpoint inhibitor.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Racial Disparities Seen in PET/CT Imaging for Lung Cancer
TUESDAY, June 23, 2020 -- Black and Hispanic patients are less likely to undergo guideline-recommended imaging at diagnosis of non-small cell lung cancer, according to a study recently published in the Journal of the National Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Keytruda for Certain Mesothelioma Patients
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - June 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news